Alerta

LIPID NANOPARTICLES AND USE THEREOF

Resumen de: WO2026040956A1

The present invention relates to a pharmaceutical composition of lipid nanoparticles (LNPs) and a therapeutic agent. The lipid nanoparticles (LNPs) comprise an antibody or antigen-binding fragment conjugated to the LNPs. For example, the antibody may be selected from anti-CD117 antibodies to specifically target cells or tissues expressing corresponding receptors.

KAEMPFEROL BIOMIMETIC NANOMATERIAL, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2026040105A1

Disclosed is a kaempferol mesenchymal stem cell membrane biomimetic material capable of more accurately targeting a damaged tissue. The biomimetic nanomaterial is simple to prepare, high in universality, and suitable for large-scale production. The present invention uses mesenchymal stem cell membranes to improve the biocompatibility and targeting property of the carrier and prolong the circulation time of the drug in vivo. The biomimetic nanomaterial prepared by the present invention enables targeted delivery of kaempferol to the liver, providing a novel treatment method for acute liver failure ALF.

PHARMACEUTICAL COMPOSITIONS OF SPIRONOLACTONE FOR DEEP DERMAL DRUG DELIVERY

Resumen de: US20260053821A1

Pharmaceutical compositions for the topical administration of spironolactone to the pilosebaceous unit and methods for administering the same. The pharmaceutical compositions comprise aqueous suspensions of submicron particles of spironolactone in water.

이온화 가능한 아민 지질

Resumen de: AU2024275548A1

The disclosure provides ionizable lipids and lipid nanoparticle (LNP) compositions comprising ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.

RECONSTITUTABLE DRY POWDER FORMULATIONS AND METHODS OF USE THEREOF

Resumen de: MX2025012337A

The present disclosure is directed to the use of reconstituted mRNA dry powder particles for parenteral administration. The present disclosure is also directed to a method of generating dry powder particles supplemented with appropriate excipients for optimal thermostability and in vivo expression.

がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法

Resumen de: AU2024339588A1

Formulated and/or co-formulated liposomes, lipid nanoparticle (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other diseases by utilizing a targeted drug delivery vehicle.

アルブミンおよびラパマイシンの医薬組成物

Resumen de: MX2022004989A

The present invention provides compositions (such as pharmaceutical compositions), and commercial batches of such compositions, comprising nanoparticles comprising albumin and rapamycin. The compositions (such as pharmaceutical compositions) have specific physicochemical characteristics and are particularly suitable for use in treating diseases such as cancer. Also provided are methods of making and methods of using the compositions (such as pharmaceutical compositions).

呼吸器疾患を治療するための方法および組成物

Resumen de: US2024423926A1

Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

治療用組成物のための開裂可能なリンカー含有イオン化脂質及び脂質担体

Resumen de: TW202438045A

The present disclosure relates to a lipid compound of formula (AL-GI):, having various cleavable linkers defined by the variables Z1 and Z2. The present disclosure also relates to a lipid carrier or lipid nanoformulation employing the lipid compound, and the use of the lipid compound in a pharmaceutical composition as well as for a method of delivering a therapeutic agent.

体内構造物の間で凝集することなく圧縮可能な多糖類架橋コロイド粒子、及びこの生体内注入用改質剤としての用途

Resumen de: CN121001754A

The present invention relates to a non-vascular injection formulation comprising nanoparticles, the hydrodynamic diameter of which is adjusted to 2 to 20 nm and the surface charge of which is adjusted to-20 to 0 mV by hydration of hydrophilic functional groups exposed on the surface of the nanoparticles such that the nanoparticles do not permeate into or expel into the capillaries of the administration site, the nanoparticles are only selectively excreted into the peripheral lymphatic vessel, but only selectively excreted into the peripheral lymphatic vessel, wherein the nanoparticles: (i) themselves are therapeutic agents; and/or (ii) a carrier for other drugs, thereby providing a drug form in which the nanoparticles are expelled only into the peripheral lymphatic vessel when injected into a tissue region without intravenous administration, thereby extending the residence time at the injection site. Nanoparticles having adjusted hydrodynamic diameter and surface charge according to the present invention can be excreted from the body within a week after administration without any residue at the site of administration, when designed as contrast agents exhibiting a T1MRI contrast effect and injected into tissues in the vicinity of the blood vessel, the nanoparticles can be used as contrast agents that exhibit a T1MRI contrast effect. Peripheral and/or central lymphatic vessels may be selectively imaged without venous contamination.

静脈汚染のないリンパ管造影剤

Resumen de: CN121001754A

The present invention relates to a non-vascular injection formulation comprising nanoparticles, the hydrodynamic diameter of which is adjusted to 2 to 20 nm and the surface charge of which is adjusted to-20 to 0 mV by hydration of hydrophilic functional groups exposed on the surface of the nanoparticles such that the nanoparticles do not permeate into or expel into the capillaries of the administration site, the nanoparticles are only selectively excreted into the peripheral lymphatic vessel, but only selectively excreted into the peripheral lymphatic vessel, wherein the nanoparticles: (i) themselves are therapeutic agents; and/or (ii) a carrier for other drugs, thereby providing a drug form in which the nanoparticles are expelled only into the peripheral lymphatic vessel when injected into a tissue region without intravenous administration, thereby extending the residence time at the injection site. Nanoparticles having adjusted hydrodynamic diameter and surface charge according to the present invention can be excreted from the body within a week after administration without any residue at the site of administration, when designed as contrast agents exhibiting a T1MRI contrast effect and injected into tissues in the vicinity of the blood vessel, the nanoparticles can be used as contrast agents that exhibit a T1MRI contrast effect. Peripheral and/or central lymphatic vessels may be selectively imaged without venous contamination.

核酸ベースのがんワクチンおよびその方法

Resumen de: CN120769913A

Compositions and methods of use thereof are described herein. The compositions described herein may comprise a single-stranded trimeric nucleic acid encoding a first T cell epitope, a beta2-microglobulin, and an MHC class I heavy chain sequence. The methods described herein can be used to activate and/or expand antigen presenting cells. The methods described herein may also be used to treat or prevent viral infections, bacterial infections, parasitic infections, and/or cancer in a subject.

イオン化可能なカチオン性化合物

Resumen de: MX2025009357A

Novel ionizable lipid compounds of Formula I are provided. The use of the compounds in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, and these may be used in the delivery of the therapeutic and in methods of treating certain conditions or for inducing an immune response.

呼吸器合胞体ウイルスｍＲＮＡワクチン

Resumen de: CN120500351A

Provided herein is a respiratory syncytial virus (RSV) vaccine composition comprising: a messenger ribonucleic acid (mRNA) comprising an open reading frame (ORF) encoding an RSV mutant F B strain protein, and optionally an mRNA comprising an ORF encoding an RSV mutant F A strain protein; and methods of inducing an immune response against RSV by administering an effective amount of the RSV vaccine composition to a subject in need thereof. Also provided herein is a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine composition comprising: an mRNA comprising an ORF encoding an RSV mutant F A strain protein, an mRNA comprising an ORF encoding an RSV mutant F B strain protein, and an mRNA comprising an ORF encoding an hMPV F protein; and methods of inducing an immune response against RSV and hMPV by administering to a subject in need thereof an effective amount of the RSV and hMPV vaccine composition.

FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES

Resumen de: EP4700017A2

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R^2a, R^2b, R^3a, R^3b, R⁷, R⁸, R⁹, L¹, L², G¹, G², G³, b, and c are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

VACCINE COMPOSITIONS AND USES THEREOF

Resumen de: WO2024220936A1

The present disclosure provides vaccine compositions comprising a plurality of distinct antigens. Also provided are nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens. The plurality of distinct antigens comprises a combination of influenza antigens. The vaccine composition can be formulated for delivery as a mRNA/LNP, a recombinant protein, a virus-like particle (VLP), or DNA. Methods of preventing an influenza infection and methods of inducing an immune response are also disclosed.

DELIVERY OF NUCLEIC ACIDS USING A TARGETED PEPTIDE CARRIER SYSTEM

Resumen de: WO2024220878A1

A layer-by-layer ELP-nucleic acid (NA) nanoparticle (LENN) complex for targeted delivery of a therapeutic NA cargo to tumor cells; a method of formulating a LENN complex using a layer-by-layer deposition process (LbL); LENN complex formulations; pharmaceutical compositions comprising a LENN complex formulations; and methods of treating bladder cancer in a subject via LENN-mediated delivery of a therapeutic NA cargo.

CONJUGATED POLYETHYLENEIMINE COMPOUNDS AND COMPOSITIONS, AND USES THEREOF FOR THE TREATMENT OF ATHEROSCLEROSIS, CARDIOVASCULAR, AND LUNG DISEASE

Resumen de: WO2024220742A1

Provided herein are lipid conjugated polyethyleneimine (PEI) compounds of Formula (I), which are useful to form delivery systems, such as lipid nanoparticles, for delivery of agents (e.g., nucleic acid molecules) to cells (e.g., endothelial cells). Also provided herein are methods for treating atherosclerosis, a cardiovascular disease, a pulmonary hypertension (e.g, pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease, comprising administering to a subject a pharmaceutical composition comprising lipid conjugated polyethyleneimine (PEI) compounds of Formula (I), an agent, and a pharmaceutically acceptable excipient.

TIMESCALE-GUIDED MICROFLUIDIC SYNTHESIS OF POLYPHENOL-IRON III NETWORK NANOCAPSULES OF HYDROPHOBIC DRUGS

Resumen de: WO2024220674A1

A scalable method of continuous microfluidic synthesis of tannic acid-iron III (TA-FeIII) network (TFN) nanocapsules of a hydrophobic drug; a scalable method of continuous microfluidic synthesis of epigallocatechin-3-gallate iron III (EGCG-FeIII) network, (EFN) nanocapsules; hydrophobic drug nanocapsules synthesized in accordance with the method; and a method of administering a hydrophobic drug to a patient in need thereof by administering to the patient the hydrophobic drug nanocapsules.

CAPSID VARIANTS AND USES THEREOF

Resumen de: US2025319207A1

Aspects of the disclosure relate to compositions and methods for delivering a transgene (e.g., a transgene encoding one or more gene products) to a target cell (e.g., an ocular cell). The disclosure is based, in part, on adeno-associated virus (AAV) capsid protein variants and methods of using same for delivery of a transgene.

LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND FORMULATIONS

Resumen de: MX2025012462A

The present disclosure describes compositions, nanoparticles (such as lipid nanoparticles), and/or lipid nanoparticle compositions and methods of their use.

DELIVERY OF POLYNUCLEOTIDES FROM LIPID NANOPARTICLES COMPRISING RNA AND IONIZABLE LIPIDS

Resumen de: WO2024220625A1

Provided herein is a method for delivering an RNA composition to a subject for in vivo production of a protein or a peptide in the subject, comprising administering to the subject an RNA composition comprising a polynucleotide that encodes a protein or a peptide, formulated within (a) a plurality of lipid nanoparticles (LNP) comprising synthetic structural lipids and an ionizable lipid, or (b) a lipid reconstructed natural messenger packs (LNMPs) comprising natural lipids and an ionizable lipid. Also provided herein are methods for treating diseases or disorders associated with the gastrointestinal tract, stomach, small or large intestine, mesenteric lymph node, pancreas, colon or rectum, caecum, and/or spleen, comprising orally or enterally administering the RNA composition described herein.

SELF-DESTRUCTING CAPSULE FOR TIMELY RELEASE OF ACTIVE INGREDIENTS

Resumen de: KR20260025932A

본 발명은 담지된 유효 물질을 지속적으로 방출할 수 있는 자가 파괴 무기 소재 마이크로 캡슐 및 이의 제조 방법에 관한 것이다. 본 발명은 캡슐의 크기와 캡슐화 성분의 함량 조절을 통해 캡슐 벽의 두께를 조절하였다. 이를 통해 유효 성분의 방출이 시작되는 시점 및 방출 속도 조절의 효과를 얻을 수 있다.

암로디핀 약물 표적 전달 시스템 및 이의 제조 방법과 용도

Resumen de: WO2026036420A1

Disclosed are an amlodipine drug targeted delivery system and a preparation method therefor. The targeted delivery system can improve the targeting property of amlodipine in preventing hepatic ischemia-reperfusion injury and is simple to prepare, highly feasible, and highly practical. The amlodipine drug targeted delivery system (Am@EXOs) prepared in the present invention enables a targeted distribution of amlodipine in the livers of hepatic ischemia-reperfusion injury model mice and precise inhibition of calcium ion overload within hepatocytes by means of a minimum dose of amlodipine, thereby reducing cell injury, improving the targeting property of amlodipine in preventing hepatic ischemia-reperfusion injury, and reducing the cost of using amlodipine.

がんを治療するための治療薬としての腫瘍溶解性ウイルス

Nº publicación: JP2026506348A 24/02/2026

Solicitante:

イムヴィルクスピーティーワイリミテッド

Resumen de: CN120603935A

The present invention relates to compositions and methods for treating cancer using oncolytic viruses, components thereof, and/or derivatives thereof. In particular, the present invention relates to modified picornaviruses comprising changes in one or more of its capsid proteins that confer enhanced binding capacity to cancer cells.